For better understanding the role of sulbactam and promoting its clinical application study as an anti-cerebral ischemia medication, the primary aim of the present study was to elucidate the role of p38 MAPK played in the sulbactam-induced neuronal protection and GLT-1 up-regulation against ischemia. This evidence concerns the gene SLC1A2 and brain ischemia.